Categories: Corporate and commercial, Intellectual Property, Life Sciences, Pharma, Biotech, Startup Desk
Oncobit, a leading Swiss company in precision oncology, announces a strategic partnership with ID Solutions, a French company specializing in developing innovative diagnostic solutions in oncology. The goal of this collaboration is to accelerate and simplify cancer diagnosis and monitoring through digital PCR.
Together, the two companies will develop a new generation of user-friendly oncology tests designed to support clinicians in making faster and more personalized treatment decisions. All tests developed under this partnership will comply with IVDR (In Vitro Diagnostic Regulation), meeting European regulatory requirements for clinical diagnostic use.
The patented technologies of ID Solutions and Oncobit form a solid foundation for delivering highly sensitive and reliable oncology diagnostics that can be used both in major hospitals and decentralized laboratories. This paves the way for cancer care that is faster, more personalized, and more accessible.
VISCHER advised Oncobit on all Swiss legal issues related to the partnership. The VISCHER team was led by Christian Wyss (Partner, Life Sciences) with Luzius Zumstein (Managing Associate, Life Sciences).
Author: Christian Wyss
